Gibson Christopher's Form 4 filing
Recursion Pharmaceuticals, Inc. (RXRX) · filed Jul 8, 2022
- Accession no.
- 0001209191-22-041710
- Filed
- Jul 8, 2022
- Trade date
- Jul 7, 2022
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 10 non-derivative transactions and 5 derivative transactions. Open-market sales total $358.7K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Gibson ChristopherCIK 0001856369 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 7, 2022 | Class A Common Stock | MOption exerciseAcquired | +31,250 | $2.48 | +$77,500 | 547,518 | Direct | |
| Jul 7, 2022 | Class A Common Stock | SSaleDisposed | −18,614 | $9.04F2 | −$168,270.56 | 528,904 | Direct | |
| Jul 7, 2022 | Class A Common Stock | CConversionAcquired | +18,500 | $0.00 | $0 | 547,404 | Direct | |
| Jul 7, 2022 | Class A Common Stock | SSaleDisposed | −18,500 | $9.07F4 | −$167,795 | 528,904 | Direct | |
| Jul 7, 2022 | Class A Common Stock | CConversionAcquired | +500 | $0.00 | $0 | 500 | Indirect | |
| Jul 7, 2022 | Class A Common Stock | SSaleDisposed | −500 | $9.06F6 | −$4,530 | 0 | Indirect | |
| Jul 7, 2022 | Class A Common Stock | CConversionAcquired | +1,000 | $0.00 | $0 | 1,000 | Indirect | |
| Jul 7, 2022 | Class A Common Stock | SSaleDisposed | −1,000 | $9.07F8 | −$9,070 | 0 | Indirect | |
| Jul 7, 2022 | Class A Common Stock | CConversionAcquired | +1,000 | $0.00 | $0 | 1,000 | Indirect | |
| Jul 7, 2022 | Class A Common Stock | SSaleDisposed | −1,000 | $9.07F10 | −$9,070 | 0 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 7, 2022 | Class A Common Stock | CConversionDisposed | −18,500 | $0.00 | $0 | 6,769,834 | Direct | |
| Jul 7, 2022 | Class A Common Stock | MOption exerciseDisposed | −31,250 | $0.00 | $0 | 950,136 | Direct | |
| Jul 7, 2022 | Class A Common Stock | CConversionDisposed | −500 | $0.00 | $0 | 543,000 | Indirect | |
| Jul 7, 2022 | Class A Common Stock | CConversionDisposed | −1,000 | $0.00 | $0 | 536,000 | Indirect | |
| Jul 7, 2022 | Class A Common Stock | CConversionDisposed | −1,000 | $0.00 | $0 | 132,875 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $9.01 to $9.14. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F4
This transaction was executed in multiple trades at prices ranging from $8.89 to $9.28. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F6
This transaction was executed in multiple trades at prices ranging from $8.91 to $9.21. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F8
This transaction was executed in multiple trades at prices ranging from $8.93 to $9.21. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F10
This transaction was executed in multiple trades at prices ranging from $8.93 to $9.22. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.